Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer
- Conditions
- Breast Cancer
- Registration Number
- NCT00002460
- Lead Sponsor
- Cancer Research UK
- Brief Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen.
PURPOSE: Phase III trial to compare the effectiveness of adjuvant therapy using tamoxifen or ovarian ablation with goserelin or both in treating women with stage I or stage II breast cancer.
- Detailed Description
OBJECTIVES: I. Determine, in a prospective, randomized, controlled trial whether the administration of a course of adjuvant tamoxifen or ablation of ovarian function results in prolongation of time to recurrence or death in patients under 50 years of age with operable carcinoma of the breast. II. Determine how hormone manipulation affects mood and sexual functioning in these patients.
OUTLINE: This is a randomized study. Patients are stratified by clinician. All patients are randomized following primary therapy, which, in addition to surgery, may include local irradiation, perioperative cyclophosphamide, or up to 6 cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF) for high-risk patients. Clinicians may elect to randomize patients to all groups or to only those groups including tamoxifen. The first group receives no further therapy. Then second group receives tamoxifen daily for at least 2 years. The third group receives ovarian ablation with goserelin via monthly injection for at least 2 years. The final group receives ovarian ablation with goserelin plus daily tamoxifen for at least 2 years. All patients are followed every 3 months for 2 years, every 6 months for 3 years, then annually.
PROJECTED ACCRUAL: 800 to 1,000 patients will be entered.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (33)
Hopital De Braine-L'Alleud-Waterloo
🇧🇪Braine-L'Alleud, Belgium
Institut Jules Bordet
🇧🇪Brussels, Belgium
U.Z. Sint-Rafael
🇧🇪Leuven, Belgium
Royal Sussex County Hospital
🇬🇧Brighton, England, United Kingdom
Castle Hill Hospital
🇬🇧Cottingham, England, United Kingdom
Walsgrave Hospital
🇬🇧Coventry, England, United Kingdom
Mayday University Hospital
🇬🇧Croydon, England, United Kingdom
Huddersfield Royal Infirmary
🇬🇧Huddersfield, West Yorks, England, United Kingdom
Cookridge Hospital
🇬🇧Leeds, England, United Kingdom
Whittington Hospital
🇬🇧London, England, United Kingdom
Scroll for more (23 remaining)Hopital De Braine-L'Alleud-Waterloo🇧🇪Braine-L'Alleud, Belgium